The clinical trial of Sansheng Guojian's il-4Ra monotogena was approved by the FDA.

Teridonderitis affects 18-25 million Americans, and about 300,000 adults are in urgent need of medication.
in China, the prevalence of especially dermatitis has been rising steadily over the past 20 years.
according to statistics, china's about 2.3 million young people suffering from aspecific dermatitis, children also reached 2 million to 3 million.
in recent years, with the rapid development of China's urbanization and industrialization, the incidence of especialder dermatitis in China has gradually increased.
IL-4Ra is part of the signalconducting complex of interleukin 4 (IL-4) and interlemic 13 (IL-13), which plays a key role in the pathogenesis of adhocytekinitis.
611 can be able to inhibit IL-4Ra, block the transmission of IL-4 and IL-13 signalto the role of remission of diseases such as adhelytetheritis.
corticosteroids are currently the most widely used drugs for the treatment of such diseases, but their more serious side effects limit their use, so there is still a wide range of unmet clinical needs for these diseases.
our antibody drug 611 is expected to bring new treatment options for patients with teriolyderitis.
.